7 results on '"Gonzalez-Alvarez B"'
Number of results to display per page
Search Results
2. Machine Learning Application for Particle Physics: Mexico’s Involvement in the Hyper-Kamiokande Observatory
- Author
-
Cuen-Rochin, S., primary, de la Fuente, E., additional, Falcon-Morales, L., additional, Gamboa Goni, R., additional, Tomatani-Sanchez, A. K., additional, Orozco-Luna, F., additional, Torres, H., additional, Lozoya, J., additional, Baeza, J. A., additional, Flores, J. L., additional, Navarro-Garcia, B., additional, Veliz, B., additional, Lopez, A., additional, and Gonzalez-Alvarez, B., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis
- Author
-
López-Longo, Francisco Javier, Seoane-Mato, Daniel, Martín-Martínez, María A., Sánchez-Alonso, Fernando, Escudero, C., Chozas, N., Maries, I., Fernandez, A., Medina, F., Ureña, I., Irigoyen, V., Lopez, M., Espiño, P., Manrique, S., Collantes, E., Font, P., Ruiz, D., Granados, M., Pozuelo, M. J., Moreno, I., Garcia Lopez, A., Pina, J. M., Rosello, R., Vazquez, C., Beltrán, J., Pecondón, A., Giménez, E., Jimenez, F., Marzo, J., Medrano, M., Babio, J., Tinture, T., Gonzalez, S., Ordas, C., Garcia, M. E., Ballina y Alonso S, J., Espadaler, L., Fernandez, J., Fiter, J., Bustabad, S., Rodríguez, C., Naranjo, A., Ojeda, S., Tornero, J., Piqueras, J. A., Judez, E., Sanchez, G., Pantoja, L., Lopez, C., Medina, J., Iglesias, G., Alvarez, M., Alegre, J., Colazo, M. R., Alonso, J. L., Alvarez, B., Perez Sandoval, T., Del Pino, J., Montilla, C., Gomez, S., Lopez, R., Sanchez, M., Arasa, F. X., Castro, S., Ordoñez, S., Boquet, D., Calvet, J., de la Fuente, D., Rios, V., Nolla, M., Martinez, A., Belmonte Serrano, M. A., Negueroles, R., Garcia, J., Gamero y E del Rincon, F., Veroz, R., Perez-Pampin, E., Fernandez, L., Miguelez, R., Godo, J., Ortíz, A. M., Vicente, E., Tomero, E., Casado, A., Aria, M. J, Cuende, E., Bohorquez, C., Rodriguez, J. M., Aragon, A., Garcia, J., Zubieta, J., Martinez, C., Mateo, I., de Juanes y E Enriquez, A, Lopez-Longo, F. J., Maese, J., Pagan, E., Rubira, M. J., Mesa, P., Rivera, N., Rodriguez, C., Gonzalez Alvarez, B., Zea, A., Diaz-Miguel, C., Cifuentes, A., and emAR II Group
- Published
- 2018
- Full Text
- View/download PDF
4. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
- Author
-
Prieto-Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela-Casasempere P, Narvaez J, Aldasoro V, Maiz O, Fernandez-Lopez C, Gonzalez M, Melero R, Villa-Blanco I, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Sanchez-Martin J, Fernandez E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Galindez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gomez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Gonzalez J, De Dios J, Andreu J, de Pedro I, Revenga M, Valdivieso J, Rosa R, De la Morena I, Fernandez-Llanio N, Labrador E, Roman-Ivorra J, Ortiz-Sanjuan F, Garcia-Valle A, Gallego A, Iniguez C, Garrido-Punal N, De la Torre R, Lopez-Gonzalez R, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Feijoo M, Fernandez C, Rua-Figueroa I, Conesa A, Arija S, Gonzalez-Gay M, and Blanco R
- Published
- 2022
5. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review
- Author
-
Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R
- Subjects
Takayasu's arteritis ,cDMARDs ,biological therapy ,Caucasian ,Tocilizumab - Abstract
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
- Published
- 2021
6. TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
- Author
-
Prieto-Pena D, Bernabeu P, Vela-Casasempere P, Narvaez J, Fernandez-Lopez C, Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Ortego N, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Arija S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Sanjuan F, de Pedro I, Valdivieso J, Laura P, Rosa R, Fernandez-Llanio N, de la Torre R, Suarez S, Montesa M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R
- Published
- 2021
7. Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project
- Author
-
Garcia-Gomez, C, Martin-Martinez, M, Fernandez C, Castaneda, S, Gonzalez-Juanatey, C, Sanchez-Alonso, F, Gonzalez-Fernandez, M, Sanmarti, R, Garcia-Vadillo, J, Fernandez-Gutierrez, B, Garcia-Arias, M, Manero, F, Senabre, J, Rueda-Cid, A, Ros-Exposito, S, Pina-Salvador, J, Erra-Duran, A, Moller-Parera, I, Llorca, J, Gonzalez-Gay, M, Gonzalez de Rabago, E, Blanco Morales, E, Fernandez Lopez, J, Oreiro Villar, N, Atanes Sandoval, A, Blanco Garcia, F, Alegre De Miquel, C, Gonzalez Fernandez, M, Huguet Codina, R, Yoldi, B, Ramentol, M, Avila, G, Marsal Barril, S, Steiner, M, Munoz, S, Gamero, F, Garcia Toron, J, Moreno Gil, M, Mas, A, Espino, P, Ros, I, Ibanez, M, Murillo, C, Piqueras, J, Berman, H, Cabrera, S, Ruiz, V, Fontsere Paton, O, Fernandez Gutierrez, B, Abasolo, L, Fabregas, M, Romera Baures, M, Nolla, J, Gonzalez-Alvaro, I, Tomero Muriel, E, Garcia de Vicuna, R, Fernandez Nebro, A, Belmonte Lopez, M, Urena, I, Irigoyen, M, Coret Cagigal, V, Lopez Gonzalez, R, Pielfort Garrido, D, Sampedro Alvarez, J, Garcia Aparicio, A, Belmonte Gomez, R, Granados Bautista, P, Hernandez Sanz, A, Sanchez Gonzalez, C, Bachiller, J, Zea, A, Jimenez Zorzo, F, Gimenez Ubeda, E, Marzo Gracia, J, Beltran Audera, C, Medrano, M, Pecondon, A, Erausquin, C, Ojeda, S, Carlos Quevedo, J, Francisco, F, Rodriguez Lozano, C, Babio Herraez, J, Lopez Longo, F, Gerona, D, Gonzalez Fernandez, C, Carreno, L, Monteagudo, I, del Pino, J, Sanchez Gonzalez, M, Corrales, A, Enriqueta Peiro, M, Rosas, J, Rotes, I, Moreno, E, Erra, A, Grado, D, Calvo, J, Rueda, A, Moller, I, Rodriguez, I, Barbadillo, C, Raya, E, Morales, P, Nieto, A, Jimenez, I, Magro, C, Ruibal Escribano, A, Ros Exposito, S, Sanchez Nievas, G, Judez Navarro, E, Sianes Fernandez, M, Garcia Morales, M, Labiano Bastero, I, Consuegra, G, Palmou, N, Martinez Pardo, S, Pujol, M, Riera Alonso, E, Salvador, G, Gonzalez Alvarez, B, Cantabrana, A, Bustabad, S, Delgado, E, Munoz, A, Rodriguez Montero, S, Maria Jimenez, L, Rivera Redondo, J, Gonzalez Hernandez, T, Gonzalez Polo, F, Menor Almagro, R, Moreno, J, Giner Serret, E, Lannuzzelli Barroso, C, Cebrian Mendez, L, Teresa Navio, M, Fernandez Carballido, C, Pagan, E, Mesa del Castillo, P, Naredo, E, Cruz, A, Turrion, A, Mateo, I, Sanchez, J, Galindo, M, Garcia Gonzalez, J, Collantes, E, Ruiz, D, Font, P, Bonilla, G, Lopez Meseguer, A, Moreno, M, Moreno Martinez, M, Beteta Fernandez, M, Linares, L, Morcillo, M, Gonzalez Gomez, M, Aramburu, J, Rivera, N, Fernandez Berrizbeitia, O, Garcia Vivar, M, Riera, M, Maria Leon, Y, Maymo, J, Amirall, M, Iniesta Escolano, S, Sanchez Serrano, S, Lis Bona, M, Fiter, J, Fernandez Melon, J, Espadaler, L, Maiz, O, Belzunegui, J, Banegil, I, Diaz, C, Valls, R, Castellvi, I, Bonet, M, Moreno Ruzafa, E, Calvo Alen, J, Perez Sandoval, T, Revuelta Evrard, E, Godo, J, Fernandez Espartero, C, Navarro Blasco, F, Antonio Gonzalez, J, Miranda-Filloy, J, and CARMA Project Collaborative Grp
- Subjects
musculoskeletal diseases ,psoriatic arthritis ,lipids ,stomatognathic diseases ,cardiovascular disease ,lipoprotein(a) ,ankylosing spondylitis ,spondyloarthritis - Abstract
Objective Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors. Methods A baseline analysis was made of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and controls included in the CARMA project (CARdiovascular in RheuMAtology), a 10-year prospective study evaluating the risk of CV events in chronic inflammatory rheumatic diseases. A multivariate logistic regression model was performed using hyperlipoproteinaemia( a) (Lp(a) >50 mg/dl) as a dependent variable and adjusting for confounding factors. Results 19.2% (95% CI: 16.80-22.05) of the SpA patients [20.7% (95% CI: 16.91-24.82) of those with AS and 17.7% (95% CI: 14.15-21.75) of those with PsA] and 16.7% (95% CI: 13.23-20.86) of the controls had hyperlipoproteinaemia(a) (p=0.326). Adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinaemia(a) than controls (OR: 1.43, 95% CI: 1.00-2.04; p=0.05), especially those with AS (OR: 1.81, 95% CI: 1.18-2.77; p=0.007). In the adjusted model, apolipoprotein B in all patients, non-steroidal anti-inflammatory drugs in AS, and female sex in PsA, were associated with hyperlipoproteinaemia(a). No disease-specific factors associated with hyperlipoproteinaemia(a) were identified. Conclusion SpA patients show a moderately increased risk of hyperlipoproteinaemia(a) compared to controls, especially those with AS. Lp(a) determination may be of interest to improve the CV risk assessment in SpA patients.
- Published
- 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.